Display options
Cite
Yang W, Shibamoto T, Kuda Y, et al. β₂-Adrenoceptor Blockade Deteriorates Systemic Anaphylaxis by Enhancing Hyperpermeability in Anesthetized Mice. Allergy Asthma Immunol Res. 2018;10(1):52-61doi: 10.4168/aair.2018.10.1.52.
Yang, W., Shibamoto, T., Kuda, Y., Zhang, T., Tanida, M., & Kurata, Y. (2018). β₂-Adrenoceptor Blockade Deteriorates Systemic Anaphylaxis by Enhancing Hyperpermeability in Anesthetized Mice. Allergy, asthma & immunology research, 10(1), 52-61. https://doi.org/10.4168/aair.2018.10.1.52
Yang, Wei, et al. "β₂-Adrenoceptor Blockade Deteriorates Systemic Anaphylaxis by Enhancing Hyperpermeability in Anesthetized Mice." Allergy, asthma & immunology research vol. 10,1 (2018): 52-61. doi: https://doi.org/10.4168/aair.2018.10.1.52
Yang W, Shibamoto T, Kuda Y, Zhang T, Tanida M, Kurata Y. β₂-Adrenoceptor Blockade Deteriorates Systemic Anaphylaxis by Enhancing Hyperpermeability in Anesthetized Mice. Allergy Asthma Immunol Res. 2018 Jan;10(1):52-61. doi: 10.4168/aair.2018.10.1.52. PMID: 29178678; PMCID: PMC5705484.
Copy Download .nbib Format: NLM
Share it on

Allergy Asthma Immunol Res. 2018 Jan;10(1):52-61. doi: 10.4168/aair.2018.10.1.52.

β₂-Adrenoceptor Blockade Deteriorates Systemic Anaphylaxis by Enhancing Hyperpermeability in Anesthetized Mice.

Allergy, asthma & immunology research

Wei Yang, Toshishige Shibamoto, Yuhichi Kuda, Tao Zhang, Mamoru Tanida, Yasutaka Kurata

Affiliations

  1. Department of Physiology II, Kanazawa Medical University, Uchinada, Japan.
  2. Department of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang, China.
  3. Department of Physiology II, Kanazawa Medical University, Uchinada, Japan. [email protected].
  4. Department of Colorectal and Hernia Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

PMID: 29178678 PMCID: PMC5705484 DOI: 10.4168/aair.2018.10.1.52

Abstract

PURPOSE: Patients treated with propranolol, a nonselective β-adrenoceptor antagonist, develop severe anaphylaxis, but the mechanism remains unknown. We determined effects of β₁- and β₂-adrenoceptor antagonists on the anaphylaxis-induced increase in vascular permeability in mice.

METHODS: In anesthetized ovalbumin-sensitized C57BL mice, mean arterial blood pressure (MBP) was measured, and Evans blue dye extravasation and hematocrit (Hct) were assessed at 20 minutes after antigen injection. The following pretreatment groups (n=7/group) were studied: (1) sensitized control (non-pretreatment), (2) propranolol, (3) the selective β₂-adrenoceptor antagonist ICI 118,551, (4) the selective β₁-adrenoceptor antagonist atenolol, (5) adrenalectomy, (6) the selective β₂-adrenoceptor agonist terbutaline, and (7) non-sensitized groups.

RESULTS: The antigen injection decreased MBP, and increased Hct and vascular permeability in the kidney, lung, mesentery, and intestine, but not in the liver or spleen. Pretreatment with ICI 118,551, propranolol and adrenalectomy, but not atenolol, reduced the survival rate and augmented the increases in Hct and vascular permeability in the kidney, intestine, and lung as compared with the sensitized control group. Pretreatment with terbutaline abolished the antigen-induced alterations. Plasma epinephrine levels were increased significantly in the sensitize control mice.

CONCLUSIONS: Blockade of β₂-adrenoceptor can deteriorate systemic anaphylaxis by augmenting hyperpermeability-induced increase in plasma extravasation by inhibiting beneficial effects of epinephrine released from the adrenal glands in anesthetized mice.

Copyright © 2018 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease

Keywords: Anaphylactic shock; Evans blue dye; anesthetized mice; epinephrine; vascular leakage; β-blocker

Conflict of interest statement

There are no financial or other issues that might lead to conflict of interest.

References

  1. Anaesth Intensive Care. 1986 Feb;14(1):17-21 - PubMed
  2. J Allergy Clin Immunol. 2005 Mar;115(3):584-91 - PubMed
  3. J Immunol. 1965 Jul;95:1-8 - PubMed
  4. Cardiol J. 2017;24(4):403-408 - PubMed
  5. J Allergy Clin Immunol. 2005 Mar;115(3):449-57; quiz 458 - PubMed
  6. Shock. 2008 Jun;29(6):733-9 - PubMed
  7. Inflammation. 1995 Feb;19(1):1-8 - PubMed
  8. Am J Physiol Heart Circ Physiol. 2013 Dec;305(12):H1807-16 - PubMed
  9. Am J Physiol Cell Physiol. 2004 Nov;287(5):C1246-55 - PubMed
  10. Circulation. 2004 Oct 26;110(17):2708-12 - PubMed
  11. Am J Respir Cell Mol Biol. 2016 Oct;55(4):476-486 - PubMed
  12. Drug Saf. 1995 May;12(5):299-304 - PubMed
  13. Am J Physiol Regul Integr Comp Physiol. 2007 Nov;293(5):R1947-53 - PubMed
  14. J Physiol. 1952 Oct;118(2):228-57 - PubMed
  15. Microcirculation. 2011 Feb;18(2):118-27 - PubMed
  16. Microcirculation. 2015 May;22(4):237-48 - PubMed
  17. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2286-97 - PubMed
  18. Circ Res. 2007 Dec 7;101(12):1274-82 - PubMed
  19. Curr Opin Cell Biol. 2010 Oct;22(5):651-8 - PubMed
  20. J Biol Chem. 2009 Feb 20;284(8):5381-94 - PubMed
  21. Hellenic J Cardiol. 2013 Sep-Oct;54(5):341-7 - PubMed
  22. FASEB J. 2007 Sep;21(11):2776-86 - PubMed
  23. Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):337-41 - PubMed
  24. J Immunol. 1989 Mar 15;142(6):1982-5 - PubMed
  25. Life Sci. 2014 Oct 29;116(2):98-105 - PubMed
  26. Nat Commun. 2015 Apr 10;6:6725 - PubMed
  27. Trends Cell Biol. 2009 Jan;19(1):8-15 - PubMed
  28. Exp Lung Res. 2013 Apr;39(3):119-29 - PubMed
  29. Anesthesiology. 2011 Mar;114(3):614-23 - PubMed
  30. Am J Physiol Cell Physiol. 2015 Jan 15;308(2):C164-75 - PubMed
  31. Am J Respir Cell Mol Biol. 2012 Apr;46(4):551-8 - PubMed
  32. Gen Pharmacol. 1999 May;32(5):597-602 - PubMed
  33. Science. 1978 Jul 14;201(4351):157-9 - PubMed
  34. Inflammation. 1991 Oct;15(5):347-54 - PubMed
  35. J Cardiovasc Pharmacol. 1990 May;15(5):720-8 - PubMed
  36. Cell Tissue Res. 1978 Jul 10;190(3):371-82 - PubMed

Publication Types